Publikationer av / inom följande

Kristina Forslind

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, Cöster L, Forslind K, van Vollenhoven R, Heimbürger M. RMD Open. 2016 Jan 14;2(1):e000133.

Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.

van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Sasso EH, Hwang CC, Segurado OG, Geborek P. Arthritis Rheumatol. 2015 Nov;67(11):2855-60.

Genetic Factors for the Severity of ACPA-negative Rheumatoid Arthritis in 2 Cohorts of Early Disease: A Genome-wide Study.

de Rooy DP, Tsonaka R, Andersson ML, Forslind K, Zhernakova A, Frank-Bertoncelj M, de Kovel CG, Koeleman BP, van der Heijde DM, Huizinga TW, Toes RE, Houwing-Duistermaat JJ, Ospelt C, Svensson B, van der Helm-van Mil AH. J Rheumatol. 2015 Aug;42(8):1383-91.